Dara-CyBorD

DRUG3 trials

Sponsors

Peking University People's Hospital, Nexcella Inc.

Conditions

Light Chain (AL) AmyloidosisMonoclonal Gammopathy of Renal SignificanceMonoclonal Gammopathy of Renal Significance (MGRS)

Phase 2

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

RecruitingNCT06418477

Peking University People's HospitalMonoclonal Gammopathy of Renal Significance

Start: 2024-06-15End: 2026-12-31Target: 20Updated: 2024-10-01

Dara-BCD for Rare MGRS

Not yet recruitingNCT06771180

Peking University People's HospitalMonoclonal Gammopathy of Renal Significance (MGRS)

Start: 2025-01-15End: 2026-06-30Target: 10Updated: 2025-01-13

Phase 3

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

Not yet recruitingNCT07709715

Nexcella Inc.Light Chain (AL) Amyloidosis

Start: 2027-01-01End: 2032-12-01Target: 260Updated: 2026-07-16